【摘要】：目的:加強替加環(huán)素使用的規(guī)范管理,評價其用藥的合理性,為臨床合理用藥提供參考。方法:抽取我院2014年6月—2015年6月應用注射用替加環(huán)素(泰閣)的出院患者病例,從病原學檢查、藥物敏感性試驗、用法用量、疾病類型等方面對105例病例進行評價分析。結(jié)果:我院應用注射用替加環(huán)素的藥物利用指數(shù)(DUI)值為1.075;105例病例中,102(97.14%)例行病原學檢查,76例(72.38%)有藥敏試驗結(jié)果;65例(61.90%)有2種以上混合感染;83例(79.05%)符合說明書給藥劑量。結(jié)論:醫(yī)療機構(gòu)需要對注射用替加環(huán)素的使用進行嚴格管理,并對其給藥療程、劑量及處方權(quán)限加以控制,防止經(jīng)驗性用藥,減少耐藥的發(fā)生。
[Abstract]:Objective: to strengthen the standardized management of the use of tegacycline, evaluate the rationality of its drug use, and provide reference for clinical rational use of tegacycline. Methods: 105 patients who were discharged with tegacycline (Taige) for injection from June 2014 to June 2015 were evaluated and analyzed in terms of etiological examination, drug sensitivity test, usage dosage, disease type and so on. Results: the drug utilization index (DUI) of tegicycline for injection in our hospital was 1.075% of 105 cases, 102.14% (97.14%) of them were pathologically examined, 76 cases (72.38%) had drug sensitivity test results, 65 cases (61.90%) had two or more mixed infections, 83 cases (79.05%) accorded with the prescribed dosage. Conclusion: medical institutions need to strictly manage the use of tegicycline for injection, and control the course, dosage and prescription authority of the administration of tegacyclin in order to prevent experiential drug use and reduce the occurrence of drug resistance.
【作者單位】： 解放軍總醫(yī)院第一附屬醫(yī)院藥劑藥理科;
【分類號】：R978.1

【參考文獻】

相關期刊論文 前8條

1 黃漢;郭鵬豪;陳怡麗;伍眾文;廖康;;兩種替加環(huán)素制劑對多重耐藥細菌的體外抗菌活性比較[J];世界臨床藥物;2016年12期

2 張斌;陳明迪;郜琨;張玉紅;任輝邦;;替加環(huán)素聯(lián)合美羅培南治療重癥感染的療效觀察[J];現(xiàn)代藥物與臨床;2015年09期

3 高金丹;方強;蘇群;;替加環(huán)素治療多重或泛耐藥鮑曼不動桿菌引起的重癥肺炎的療效評價[J];中國抗生素雜志;2015年08期

4 周洋;黃河;張家洪;;替加環(huán)素聯(lián)合頭孢哌酮舒巴坦治療多重耐藥鮑曼不動桿菌肺炎的療效觀察[J];實用醫(yī)學雜志;2015年05期

5 孫桂鳳;陳，

本文編號：2288583